Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., has appointed William Andrews, MD, FACP, as chief medical officer, effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company’s two commercial-stage products TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O’Dea, MB, BCh, BAO, FRCP(C), will serv...